ArticleScience progress
The use of the MoCA in cognitive impairment for older patients with Chronic Obstructive Pulmonary disease: A preliminary study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCognitive Impairment (CI) represents an important extra-pulmonary feature of Chronic Obstructive Pulmonary Disease (COPD), in which its prevalence remains under-recognised. The Montreal Cognitive Assessment (MoCA) is a validated screening test for detecting CI.ObjectivesThe use of the MoCA in clinically stable COPD in routine practice. Secondary aim: CI prevalence in COPD.DesignFeasibility study.MethodsQuantitative and qualitative data were collected in 30 COPD patients, aged ≥65 years, at the Outpatient Department in Modena (Italy).ResultsThe MoCA administration was on average 11 min. Patient feedback was positive. The COPD participants (mean age 75 years) viewed the test favourably and felt that understanding more about cognitive function would help improve their care. The median MoCA score was 23 with 10% of patients had moderate CI. The prevalence of CI was 84%.ConclusionThe MoCA is not time-consuming and should be incorporated in daily routine to identify CI in COPD, in which the prevalence of mild CI remains high. Results warrant further studies in larger populations to confirm feasibility in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.